Congratulations to Dr. Sean Kerby and the DelRicht clinical research team at Gulfport Memorial Hospital for the achievement of the first patient screened studywide in a major obesity and Type 2 Diabetes Mellitus (T2DM) trial. This U.S. trial evaluates the efficacy of an oral treatment for weight management in adults with obesity or overweight conditions presenting with T2DM comorbidities. As the industry looks towards more patient-centric protocols, the development of non-invasive oral therapies represents a major shift towards improving long-term patient compliance and treatment accessibility.

In the quickly evolving and competitive landscape of obesity and T2DM clinical research, ensuring the first patient screened studywide in a phase III trial is a significant landmark. This milestone underscores the site’s exceptional operational readiness, deep community engagement, and commitment to advancing next-generation therapies for obesity and T2DM.

Embedded Physician Partnership

Partnering as a Principal Investigator within the DelRicht Research site network for the last five years, Dr. Kerby contributes 22 years of medical experience, expertise, and a proven history of patient engagement to the network. Dr. Kerby is regarded for his adherence to complex protocol standards and consistent enrollment success. He has previously been recognized across multiple gout studies for achieving first patient screened and enrolled, as well as maintaining a consistent position as a top-five enroller. Operating out of Gulfport Memorial Hospital in Gulfport, Mississippi, Dr. Kerby has led over 25 clinical trials across a variety of general medicine therapeutic areas, including:

– Obesity

– Type 2 Diabetes Mellitus

– Hypertension

– Hypercholesterolemia

– Infectious Disease Vaccines

Operational Excellence

For sponsors and CROs managing study timelines, startup efficiency and rapid enrollment are critical to mitigating trial risk. Dr. Kerby’s team delivered on both by leveraging proactive protocol reviews and early patient pre-identification to achieve a 1-day timeline from site activation to first patient screening. Backed by a database of 33,000 patients and a 40% diverse population, the Gulfport team provides immediate clinical momentum for any trial. This exceptional readiness directly supports sponsor timelines while ensuring robust, diverse data capture. Commenting on the milestone, Marshall Morris, Partner at DelRicht Research, noted:

“Securing the first patient screened studywide in a competitive Phase III trial is a powerful testament to our site readiness,” said Marshall Morris, Partner at DelRicht Research. “In cardiometabolic clinical development, speed and patient engagement are everything. The precision trial management demonstrated by Dr. Kerby and his team is exactly why sponsors trust DelRicht as their site network of choice”

 

– Marshall Morris, Partner at DelRicht Research

DelRicht Research remains dedicated to partnering with leading investigators like Dr. Kerby, who combines clinical excellence, operational speed, and a patient-centered approach to advancing modern medicine.

Partnering With DelRicht Research

DelRicht Research is a nationwide, multidisciplinary network of 33 community-based sites dedicated to increasing patient participation in clinical trials. By partnering with independent physicians across a wide range of therapeutic specialties, DelRicht delivers high-quality, scalable clinical research while maintaining a community-centered approach to trial access. Through study start-up and site management, DelRicht optimizes study recruitment and data collection for sponsors and CROs.

Learn more about our current studies in general medicine, including indications like obesity and diabetes research.